Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits

World Journal of Urology

Volumn 25, Issue 5, 2007, Pages 525-529

  Shen, Zhou Jun ^a   Wang, Yi ^b   Ding, Guo Qing ^c   Pan, Chun Wu ^a   Zheng, Rong Ming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Department of Urology   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Antifibrinolytic agents; BCG vaccine; Fibronectin; Urinary bladder

Indexed keywords

4 AMINOBENZOIC ACID; 4 AMINOMETHYLBENZOIC ACID; 4-AMINOMETHYLBENZOIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; FIBRONECTIN; HEPARIN; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BLADDER; BLADDER TUMOR; DISEASE MODEL; DRUG EFFECT; INTRAVESICAL DRUG ADMINISTRATION; MALE; MICROBIOLOGY; MYCOBACTERIUM BOVIS; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT; TRANSITIONAL CELL CARCINOMA;

4-AMINOBENZOIC ACID; 6-AMINOCAPROIC ACID; ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTIFIBRINOLYTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; FIBRONECTINS; HEPARIN; MALE; MYCOBACTERIUM BOVIS; RABBITS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 34648820501     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0198-z     Document Type: Article

References (34)

1. Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180-183
2. Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PG, Oettgen HF, Melamed MR (1985) Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 25:119-123
3. Böhle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90-95
4. Syvester RJ, van der Meijden A.P, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 168:1964-1970
5. Ratliff TL, Kavoussi LR, Catalona WJ (1988) Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 139:410-414
6. Zhao W, Schorey JS, Groger R, Allen PM, Brown EJ, Ratliff TL (1999) Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem 274:4521-4526
7. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62-67
8. Böhle A, Brandau S (2003) Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170:964-969
9. Wiker HG, Harboe M (1992) The antigen 85 complex: A major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56:648-661
10. Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 144:1362-1364
11. Witjes JA, vd Meijden AP, Doesburg W, Debruyne FM (1993) Influence of fibrin clot inhibitors on the efficacy of intravesical bacillus Calmette-Guerin in the treatment of superficial bladder cancer. Eur Urol 23:366-370
12. Hudson MA, Brown EJ, Ritchey JK, Ratliff TL (1991) Modulation of fibronectin-mediated bacillus Calmette-Gúrin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51:3726-3732
13. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD Radwin HM (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124:38-40
14. Witjes JA (1997) Current recommendations for the management of bladder cancer. Drug therapy. Drugs 53:404-414
15. Lerner SP, Tangen CM, Suchatew H, Wood D, Crawford ED (2007) Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol 177:1727-1731
16. Davies M, Sabbadini E (1982) Mechanisms of BCG action. I. The induction of nonspecific helper cells during the potentiation of alloimmune cell-mediated cytotoxic responses. Cancer Immunol Immunother 14:46-53
17. Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155-158
18. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135:272-274
19. Steg A, Leleu C, Debre B, Boccon-Gibod L, Sicard D (1989) Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res 310:325-334
20. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK (2000) BCG intravesical instillations: Recommendations for side-effects management. Eur Urol 37(Suppl):33-36
21. Patard JJ, Chopin D, Boccon-Gibod L (1993) Mechanisms of action of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. World J Urol 11:165-168
22. Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136:970-974
23. Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, Catalona WJ, Ratliff TL (1986) Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol 135:268-271
24. Becich MJ, Carroll S, Ratliff TL (1991) Internalization of bacillus Calmett-Guerin by bladder tumor cells. J Urol 145:1316-1324
25. Bevers RF, Kurth KH, Schamhart DH (2004) Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 91:607-612
26. Peake P, Gooley A, Britton WJ (1993) Mechanism of interaction of the 85B secreted protein of Mycobacterium bovis with fibronectin. Infect Immun 61:4828-4834
27. Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: Initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 47:1762-1766
28. Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128:27-30
29. Badalament RA, Franklin GL, Page CM, Dasani BM, Wientjes MG, Drago JR (1992) Enhancement of bacillus Calmette-Guerin attachment to the urothelium by removal of the rabbit bladder mucin layer. J Urol 147:482-485
30. Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86:83-88
31. Martin DE, Reece MC, Maher JE, Reese AC (1988) Tissue debris at the injury site is coated by plasma fibronectin and subsequently removed by tissue macrophages. Arch Dermatol 124:226-229
32. Cheng CY, Martin DE, Leggett CG, Reece MC, Reese AC (1988) Fibronectin enhances healing of excised wounds in rats. Arch Dermatol 124:221-225
33. Grinnell F, Billingham RE, Burgess L (1981) Distribution of fibronetin during wound healing in vivo. J Invest Dermatol 76:181-189
34. Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guérin therapy for superficial bladder tumors. J Urol 144:1362-1364